Australia's largest stock trading and investment forum Australia's #1 stock forum

IDT

0.00%

12.0¢ idt australia limited

Excerpt missed... As you can see "at the request of...

First 18 Last

Share
Profile

Follow
Goldfinger1972

575 Posts.

122

04/09/21

14:47

Post #: 55833152
Share

Originally posted by Goldfinger1972: ↑

When you look at the below article from earlier this year it correlates with the IDT announcement recently as the government asked CSL to do the same thing with their facility with Novavax but they said they cant while making AZ.

Same question asked of IDT and here we are. Getting site sterile ready and on standby.

Despite both being protein-based vaccines, the AstraZeneca and Novavax vaccines require different manufacturing methods. A CSL spokesperson said the company had considered making both at once, but said there were differences between the two sets of production.

CSL said it had already “retooled” its laboratory with “significant adjustments” and “extensive preparation work” to make the AstraZeneca model.

That included new equipment, hiring workers for an “around-the-clock production schedule”, approvals for handling a live virus, and new material to allow the production of huge numbers of vaccines, the company said.

However, TND understands the government had never anticipated CSL would produce both vaccines at once, and had always hoped it would make Novavax’s model sometime in the future.

Health minister Greg Hunt told TND that Novavax’s current contract with Australia would see the 51 million doses manufactured at several sites in Europe. However, manufacturing in Australia is seen as a preferable option.

TND understands the federal government considers Novavax a long-term future option, and as a “backup” for the priority vaccines, AstraZeneca and Pfizer. Health minister Greg Hunt says Australia already has “whole of population” coverage with those two vaccines for the short-term.

However, the Novavax jab is seen as potentially having more long-term advantages.

For instance, it’s unclear whether COVID vaccines will need future booster shots after the first doses, much like annual flu jabs. Large-scale trial results for the Novavax vaccine are still being collated, but it is hoped that it might be more effective long-term if multiple or yearly jabs are required.

"I have a very strong feeling that Novavax, or one of the other protein vaccines will be the long-term option for vaccination for the world,” Professor Kelly, said.

“We always had a backup in the Novavax vaccine … And that’s showing very strong performance and quicker than we had thought.”

Expand

Excerpt missed... As you can see "at the request of government"... Sound familiar to IDT announcement?

"At the request of government, we have carefully considered our ability to simultaneously manufacture the Novavax vaccine, but unfortunately we do not have the capacity or capability to manufacture two COVID-19 vaccines involving live viruses,” a CSL spokeswoman told The New Daily on Thursday.

IDT Price at posting: 67.5¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

PR1

Fourfold skarn increase points the way to viable garnet project, says Pure

Good habits matters when it comes to finances

NOX

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

SMI

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

There are more pages in this discussion • 101 more messages in this thread...

First 18 Last

Add IDT (ASX) to my watchlist

(20min delay)
Last 12.0¢		Change 0.000(0.00%)		Mkt cap ! $51.55M

Open	High	Low	Value	Volume
11.5¢	12.0¢	11.5¢	$31.59K	268.5K

Buyers (Bids)

No.	Vol.	Price($)
1	32331	11.5¢

Sellers (Offers)

Price($)	Vol.	No.
12.5¢	16839	1

View Market Depth

No.	Vol.	Price($)
1	32331	0.115
7	406265	0.110
4	525238	0.105
3	176666	0.100
1	30000	0.099

Price($)	Vol.	No.
0.125	16839	1
0.130	136481	3
0.135	498000	3
0.140	349237	8
0.145	152627	2

Last trade - 16.10pm 19/08/2024 (20 minute delay)

IDT (ASX) Chart

Excerpt missed... As you can see "at the request of...

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Fourfold skarn increase points the way to viable garnet project, says Pure

Good habits matters when it comes to finances

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Excerpt missed... As you can see "at the request of...

Top Stories

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Fourfold skarn increase points the way to viable garnet project, says Pure

Good habits matters when it comes to finances

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News